A Chinese study found carboplatin boosts survival for triple-negative breast cancer patients with no new safety issues.

A large-scale Chinese study led by Fudan University Shanghai Cancer Center found that adding carboplatin to standard treatment significantly improved survival rates for triple-negative breast cancer patients, with a 92.3% three-year recurrence-free survival rate in the experimental group versus 85.8% in the control group, and a 36% reduction in cancer recurrence risk. High-risk patients, including those with rapidly dividing tumors, had a 98% three-year survival rate. The treatment showed no new safety concerns and supports a shift toward personalized care after surgery. Results were published in BMJ.